The dual health and economic crisis resulting from COVID-19 has brought into sharp focus the importance of ethical business conduct. Small and medium enterprises (SMEs) in the medical device and biopharmaceutical sectors have been significantly impacted, during a time when they are being called upon for major action.

Today, IFPMA joined hundreds of diverse stakeholders from more than 30 economies spanning the Asia-Pacific and beyond in a shared commitment to solidify and grow the world’s largest public-private, multi-sectoral partnership in the advancement of business ethics in the medical device and biopharmaceutical sectors, through Vision 2025.